Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens

多糖疫苗抗原的活减毒重组细菌递送

基本信息

  • 批准号:
    7432599
  • 负责人:
  • 金额:
    $ 35.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-06-01 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Bacterial polysaccharides are excellent targets for vaccine development as they are surface exposed and often the most protective antigens expressed on a pathogen. However, purified polysaccharides are generally poor immunogens, particularly if their immunogenicity is not enhanced by conjugation to a protein. Such polysaccharide-protein conjugate vaccines are often complicated and expensive to produce and difficult to deliver. In order to demonstrate the potential of a novel approach to utilize polysaccharides as vaccine candidates, we have expressed the O antigen portion of Pseudomonas aeruginosa lipopolysaccharide (IPS) on an attenuated strain of Salmonella typhimurium. We compared different routes of immunization to protect against acute P. aeruginosa pneumonia in a mouse model system and found that intranasal administration of the vaccine provides better protection than either oral or intraperitoneal delivery. However, we do not know whether it is the location, level, and/or type of antibody response that is responsible for this protection. We have also shown that intranasal delivery of this vaccine can protect mice against P. aeruginosa infections after corneal trauma or after burns, but do not know the optimal route of immunization to induce immunity at these different sites, nor do we know the effect of host factors such as cystic fibrosis on modulating the immunity induced by the attenuated recombinant S. typhimurium. Also unclear is whether such vaccines can alleviate problems associated with polysaccharide-protein conjugate vaccines including subtype specificity and subtype inhibition, and the exclusion of acid-liable O antigens. The specific aims of this grant are to (1) determine the basis for protective immunity to P. aeruginosa acute pneumonia mediated by the attenuated recombinant S. typhimurium O antigen-based vaccine, (2) determine the optimal route of immunization to protect against P. aeruginosa infections after corneal injury or burns, (3) determine whether the vaccine can protect CF mice from P. aeruginosa lung infections, and (4) test additional O antigen-based vaccines for polysaccharide expression, immunogenicity, and protection. Overall, the long-term goal of this project is to understand the basis of protection against these varied infections, which in turn will allow us to develop rational strategies for vaccine development against this important opportunistic pathogen. We anticipate that this knowledge will also be applicable to other pathogens.
描述(由申请方提供):细菌多糖是疫苗开发的极好靶点,因为它们是表面暴露的,并且通常是病原体上表达的最具保护性的抗原。然而,纯化的多糖通常是差的免疫原,特别是如果它们的免疫原性不通过与蛋白质缀合而增强。这种多糖-蛋白质缀合物疫苗通常生产起来复杂且昂贵,并且难以递送。为了证明利用多糖作为疫苗候选物的新方法的潜力,我们在鼠伤寒沙门氏菌的减毒株上表达了铜绿假单胞菌脂多糖(IPS)的O抗原部分。我们在小鼠模型系统中比较了不同的免疫途径以预防急性铜绿假单胞菌肺炎,发现鼻内接种疫苗比口服或腹膜内接种提供更好的保护。然而,我们不知道是否是抗体应答的位置、水平和/或类型负责这种保护。我们还表明,鼻内递送该疫苗可以保护小鼠在角膜创伤或烧伤后免受铜绿假单胞菌感染,但我们不知道在这些不同部位诱导免疫的最佳免疫途径,也不知道宿主因素如囊性纤维化对调节减毒重组S.鼠伤寒。同样不清楚的是,这种疫苗是否可以减轻与多糖-蛋白质缀合物疫苗相关的问题,包括亚型特异性和亚型抑制,以及排除酸不稳定的O抗原。本基金的具体目的是:(1)确定由减毒重组S.(1)确定基于鼠伤寒沙门氏菌O抗原的疫苗的最佳免疫途径,(2)确定在角膜损伤或烧伤后保护免受铜绿假单胞菌感染的最佳免疫途径,(3)确定疫苗是否可以保护CF小鼠免受铜绿假单胞菌肺部感染,和(4)测试另外的基于O抗原的疫苗的多糖表达、免疫原性和保护。总体而言,该项目的长期目标是了解针对这些不同感染的保护基础,这反过来将使我们能够制定针对这种重要的机会致病菌的疫苗开发的合理策略。我们预计,这些知识也将适用于其他病原体。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joanna B Goldberg其他文献

Joanna B Goldberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joanna B Goldberg', 18)}}的其他基金

Monoclonal Antibody to Combat Pseudomonas Aeruginosa
对抗铜绿假单胞菌的单克隆抗体
  • 批准号:
    10674274
  • 财政年份:
    2023
  • 资助金额:
    $ 35.9万
  • 项目类别:
Pyocins as antibacterials to treat Pseudomonas aeruginosa infections
脓毒素作为抗菌药物治疗铜绿假单胞菌感染
  • 批准号:
    10727705
  • 财政年份:
    2023
  • 资助金额:
    $ 35.9万
  • 项目类别:
Mechanisms of Staphylococcus aureus and Pseudomonas aeruginosa Co-existence in CF
CF中金黄色葡萄球菌和铜绿假单胞菌共存的机制
  • 批准号:
    10078252
  • 财政年份:
    2020
  • 资助金额:
    $ 35.9万
  • 项目类别:
Impact of Alginate Overproduction on P. aeruginosa LPS O Antigen Expression
海藻酸盐过量生产对铜绿假单胞菌 LPS O 抗原表达的影响
  • 批准号:
    9317789
  • 财政年份:
    2017
  • 资助金额:
    $ 35.9万
  • 项目类别:
Mechanism of Phosphorylcholination of EF-Tu on Pseudomonas aeruginosa
EF-Tu对铜绿假单胞菌的磷酸胆酸化机制
  • 批准号:
    8638629
  • 财政年份:
    2014
  • 资助金额:
    $ 35.9万
  • 项目类别:
Mechanism of Phosphorylcholination of EF-Tu on Pseudomonas aeruginosa
EF-Tu对铜绿假单胞菌的磷酸胆酸化机制
  • 批准号:
    8912974
  • 财政年份:
    2014
  • 资助金额:
    $ 35.9万
  • 项目类别:
Virulence Determinants for Host Tropism in the Burkholderia cepacia complex
洋葱伯克霍尔德菌复合体中宿主向性的毒力决定因素
  • 批准号:
    8583633
  • 财政年份:
    2013
  • 资助金额:
    $ 35.9万
  • 项目类别:
Virulence Determinants for Host Tropism in the Burkholderia cepacia complex
洋葱伯克霍尔德菌复合体中宿主向性的毒力决定因素
  • 批准号:
    8665382
  • 财政年份:
    2013
  • 资助金额:
    $ 35.9万
  • 项目类别:
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection
嘌呤生物合成作为幽门螺杆菌感染的治疗靶点
  • 批准号:
    8488407
  • 财政年份:
    2012
  • 资助金额:
    $ 35.9万
  • 项目类别:
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection
嘌呤生物合成作为幽门螺杆菌感染的治疗靶点
  • 批准号:
    8635527
  • 财政年份:
    2012
  • 资助金额:
    $ 35.9万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 35.9万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了